NIAID grantee Carl H. June, M.D., (center) led the study with co-investigators Bruce L. Levine, Ph.D., (right) and Pablo Tebas, M.D. (left), all of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Credit: Penn Medicine
View larger image.
Credit: Penn Medicine
View larger image.
 Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases |
    Visit us on the Web |
Genetic Modification of Cells Proves Generally Safe as HIV Treatment Strategy
Scientists today report initial results from humans on the safety and tolerability of a novel strategy to curb HIV disease by removing key cells from HIV-infected individuals, genetically modifying the cells to resist HIV infection and returning them to those individuals.
The basic and pre-clinical research on this strategy, which eventually might help people control HIV without drugs, was funded by NIAID.
.png)
No hay comentarios:
Publicar un comentario